Septerna Q2 2026: net loss $13.0M, cash $516.5M, SEP-479 half-life supports once-daily dosing

Septerna, Inc.

Cash, equivalents and marketable securities totaled $516.5M as of June 30, 2026; expected to fund operations into 2029.
Q2 2026 revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex a year ago; net loss narrowed to $13.0M from $24.8M.
SEP-479 Phase 1 observed elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
SEP-631 showed positive Phase 1 results; company evaluating signal-finding studies in mast cell-driven diseases; TSHR program advancing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.